## GE: GE Aerospace - XLI: Industrials

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.2% in lower entry zone (4.0-10.0%), top 9% cross-sectional ranking. Caution: MRS_5 (-0.7%) diverging from MRS_20, watch for reversal. Outperforming sector by 3.4%. Caution: declining volume (36% of avg), momentum weakening (-2.2% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($297.94)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Apollon Wealth Management LLC Increases Stake in GE Aerospace $GE**
- Source: MarketBeat | 20251228T082418 | Bullish | Relevance: 100%
- Apollon Wealth Management LLC significantly increased its stake in GE Aerospace, purchasing an additional 4,107 shares and bringing their total holdings to 27,421 shares valued at $8.249 million. This move comes as GE Aerospace has shown strong financial performance, beating Q3 earnings estimates with EPS of $1.66 and revenue of $11.31 billion, and setting optimistic FY2025 guidance. The stock benefits from a "Moderate Buy" consensus rating among analysts, despite an insider sale by SVP Russell Stokes.

**2. GE HealthCare CEO Peter Arduini is forging a new chapter while drawing on Jack Welchâ€™s legacy**
- Source: Fortune | 20251228T110202 | Somewhat-Bullish | Relevance: 75%
- GE HealthCare CEO Peter Arduini discusses leading the company post-spin-off from General Electric, drawing on GE's legacy and Jack Welch's leadership principles while adapting to modern medical technology and digital health landscapes. He highlights the company's significant increase in R&D investment and focus on lean principles, innovation, and global market strategies, particularly in China. Arduini emphasizes authenticity, communication, and empowering employees to live the company's values in his leadership approach.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Citigroup | $386 | $0 | 0% |
| 2025-12-04 | Susquehanna | $350 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Citigroup | init | Buy |
| 2025-12-04 | Susquehanna | init | Positive |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($10.00M) |
| Sells | 2 ($2.38M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.7% (+0.1%)
- Blackrock Inc.: 8.3% (+5.3%)
- FMR, LLC: 5.2% (-9.1%)
- TCI Fund Management : 4.5% (0.0%)
- Capital Internationa: 4.2% (-5.8%)

### Key Risks

1. Valuation stretched: PEG 5.8x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 5.75 signals overvaluation risk, limited margin of safety. Forward P/E 43.2x stretched relative to 16% growth. Quality metrics strong (ROE 42%, margin 18%). Balance sheet: $2.2B free cash flow. Insider buying signal ($10.0M), management confidence. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $330.4B |
| Beta | 1.41 |
| 52W Range | $159.36 - $318.06 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 5.75 |
| Forward P/E | 43.2 |
| Current P/E | 50.0 |
| YoY Growth | 15.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 6.3% to 4.2% (-2.2% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 91st percentile. MRS_5 (-0.7%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.6% shows strong absolute momentum above own 20MA. Outperforming sector by 3.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (2.60), confirming momentum. RSI neutral at 60. Volume at 36% of 20MA suggests lack of conviction. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.17% (CS: 91) | Strong |
| RSI_14 | 59.6 | Neutral |
| MACD Histogram | 2.60 | Bullish |
| vs SMA20 | 1.046x | Above |
| vs SMA50 | 1.035x | Above |
| vs SMA200 | 1.194x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $311.74
- **Stop Loss:** $297.94 (4.4% risk)
- **Target:** $332.44 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 99
- **Position Value:** $30,862.26
- **Portfolio %:** 30.86%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-01-22 (Est: $1.42)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.47 | $1.66 | +13.0% |
| 2025Q2 | $1.43 | $1.66 | +16.0% |
| 2025Q1 | $1.27 | $1.49 | +17.5% |
| 2024Q4 | $1.04 | $1.32 | +26.9% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*